Navigation Links
Natrix Separations Introduces New Leadership Team
Date:10/28/2011

BURLINGTON, Ontario, Oct. 28, 2011 /PRNewswire/ -- Natrix Separations, Inc. announced today new members of its leadership team, including John A. Chickosky as President & Chief Executive Officer and Molly S. McGlaughlin as Vice President of Business Development. Chickosky has been a member of the Natrix Board of Directors since mid-2010, and will continue to hold a board seat. McGlaughlin joined Natrix in June 2011.

C. Howie Honeyman, Ph.D. will continue as Senior Vice President, Research, Product Development & Applications and Robert Beveridge will remain as Chief Financial Officer.

The management team announcements coincide with a new round of investment from the existing slate of investors and a focused product development effort that is being conducted in close collaboration with biopharmaceutical industry leaders. The company is currently exploring additional collaboration partnerships to support this strategy.

Natrix Board Chairman Jim Iuliano commented, "John has been instrumental in assessing our technology and shaping our business strategy as a member of the board, and we are thrilled to have him leading the company during this exciting new phase of its development. He is widely respected among biopharm industry leaders and has demonstrated a deft hand in commercializing new technologies in this space."

Chickosky added, "Natrix's patented advective high-capacity chromatography technology has been well-received by the industry, and we are confident that it will deliver a step-change improvement in the way downstream processing is handled. We now have the right team and a focused plan to swiftly deliver the promise of Natrix's core technology to customers who need it to meet the challenges of a rapidly changing bioproduction environment."

Most recently, Chickosky was Chief Commercial Officer and President of the BioSystems Division of Xcellerex, Inc., where he led the development and execution of the company's commercial strategy. He brings more than 20 years of senior management experience with life science technology companies, including senior positions at Kendro Laboratory Products (now part of ThermoFisher), CARR Separations, and Sepracor, Inc. John holds a Bachelor of Science degree in Electrical Engineering and Computer Science from Santa Clara University and an MBA from St. Mary's College (California).

As Vice President of Business Development, Molly McGlaughlin is responsible for all commercial development and marketing for the company. Molly brings to Natrix more than 20 years of senior level biotechnology business development and marketing experience, most recently at Cytovance Biologics where she was Vice President of Sales and Business Development. Previously, she held commercial positions with leading life sciences companies including Avecia Biotechnology, Patheon and Tyco Healthcare. Molly is also a long-time member of the U.S. Army Reserves, where she is currently a Battalion Commander. She holds a B.S. in Biology from Norwich University, an M.eD. from the University of Massachusetts, Boston, and is a Doctoral candidate in the school of Business and Technology at Capella University concentrating on M&A in the Biotechnology sector.

ABOUT NATRIX SEPARATIONS Natrix Separations is commercializing a new downstream bioprocessing technology based on its patented advective chromatography platform. Natrix technology combines the superior binding capacity of conventional resin-based column chromatography with the high throughput of membrane chromatography. This performance enables a new level of flexibility in downstream processing, eliminating the reliance on fixed, capital-intensive glass or stainless chromatography columns while also reducing buffer and other consumables costs by as much as 80%. Natrix technology is packaged in a single-use format, eliminating the cleaning, sanitization, storage, and validation burdens of conventional approaches. This format speeds facility turnaround and makes complete single-use biomanufacturing operation feasible and practical.

Natrix is currently exploring collaboration programs with leading biopharmaceutical organizations to advance the commercialization of its technology.

For more information please visit www.natrixseparations.com.CONTACT:Molly McGlaughlin Natrix Separations 617-548-7927 mcglaughlin@natrixseparations.com
'/>"/>

SOURCE Natrix Separations, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Supelco(R) Introduces Breakthrough in Bioseparations Performance -- Ascentis(R) Express ES-C18 HPLC Columns
2. Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings
3. Ventana Medical Systems, Inc. Introduces Groundbreaking Laboratory Workflow Integration
4. Molecular Devices, LLC Introduces SoftMax Pro® 6 Microplate Data Acquisition and Analysis Software With Powerful New Data Analysis and Reporting Features
5. SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line
6. Olympus Introduces Worlds First Autoclavable 5mm HD Deflectable Videolaparoscope
7. Top Plastic Surgeon Introduces Worlds First VECTRA XT 3D Imaging Solution
8. Invuity Introduces Advanced Illuminated Surgical System for Breast Procedures
9. Colorcon, Inc. Introduces Opadry® 200 Optimized Performance Film Coatings
10. Quest Introduces Its Next Generation AlphaView 4MP Medical LCD
11. Honeywell Introduces New Ultra-High Barrier Film for Pharmaceutical Packaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017 The Pharmacy ... the implementation of the planned 2020 accredited education ... PTCB originally announced in 2013 that the requirement ... a road map of program changes designed to ... in the pharmacy. "We have ...
(Date:1/23/2017)... 2017  Therabron Therapeutics, Inc., a clinical-stage biotechnology ... respiratory care, today announced that the European Medicines ... granted Orphan Drug Designation for Therabron,s CG367 program, ... (BOS).  "We are pleased to have ... treat patients diagnosed with BOS following lung transplantation. ...
(Date:1/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The interventional radiology products market is expected to reach ... at a CAGR of 4.8%. This market is segmented based on ... the growth of this market are rising incidence of chronic diseases, ...
Breaking Medicine Technology:
(Date:1/24/2017)... Santa Rosa, CA (PRWEB) , ... January 24, 2017 , ... ... rates is good news for everyone and particularly good news for prostate cancer patients: ... from the diagnosis. , According to the report the cancer death rate has dropped ...
(Date:1/24/2017)... ... 2017 , ... A yellow fever outbreak in Brazil has infected over 100 ... primarily spread through contact with infected mosquitos. The outbreak has sparked increased concern about ... , According to multiple health organizations, the best way to prevent yellow fever is ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... for everyday use to improve the connection with God. “Spiritual Vitamins: A Spiritual ... author. , Published by Christian Faith Publishing, Mathai Yohannan’s new book engages the ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... ... refined coffee house-caliber protein and espresso drink, announced its CLICK® Coffee Protein Drink ... , CLICK® Coffee Protein Drink Mix has become popular among health-conscious consumers who ...
(Date:1/24/2017)... ... January 23, 2017 , ... Texas Home ... acquisitions of two personal care service companies: Padre Home Health in Corpus Christi, ... 1, 2017. , Well regarded in their respective markets, these two agencies align ...
Breaking Medicine News(10 mins):